NSF after Gadovist exposure: a case report and hypothesis of NSF development
Open Access
- 19 September 2009
- journal article
- case report
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 24 (12), 3882-3884
- https://doi.org/10.1093/ndt/gfp494
Abstract
So far no cases of nephrogenic systemic fibrosis (NSF) have been published on macrocyclical gadolinium-based contrast media (Gd-CM), assumed as low NSF risk CM due to their complex stability. In our haemodialysis-dependent patient, the first symptoms indicating NSF appeared about 16 months after the exposure to Gadovist, a macrocyclical Gd-CM, and 1 month after x-ray angiography with iodinated CM (Ultravist). This indicates that in addition to excretory renal failure and Gd-CM exposure, the loss of biosynthetic renal function could be essential for NSF development. A hypothesis of possible pathways involved in the development of NSF is presented.Keywords
This publication has 8 references indexed in Scilit:
- High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patientsNephrology Dialysis Transplantation, 2009
- Fibroblast growth factor 23 (FGF23) and the kidney.The International Journal of Artificial Organs, 2009
- Fibroblast Growth Factor 23 and Mortality among Patients Undergoing HemodialysisNew England Journal of Medicine, 2008
- Extracellular Gd-CA: Differences in prevalence of NSFEuropean Journal of Radiology, 2008
- NSF: WHAT WE KNOW AND WHAT WE NEED TO KNOW: Tissue Deposition of Gadolinium and Development of NSF: A Convergence of FactorsSeminars in Dialysis, 2008
- Nephrogenic Systemic Fibrosis: A Review and Exploration of the Role of GadoliniumAdvances in Dermatology, 2007
- Klotho converts canonical FGF receptor into a specific receptor for FGF23Nature, 2006
- Nephrogenic systemic fibrosis: An updateCurrent Rheumatology Reports, 2006